Dr. Alaa Ali, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 78
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME176846
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Georgetown University Hospital Washington, DC
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
- Regional Cancer Care Associates LLC (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 459
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 227 | 36 |
| Established patient office or other outpatient visit, 40-54 minutes | 61 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Valacyclovir (valacyclovir hcl) Other prescribers in Tampa, FL | 12 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Tampa, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $13,287 in total to this clinician.
| Kite Pharma, Inc. | $13,055 |
|---|---|
| Legend Biotech USA Inc. | $119 |
| Syndax Pharmaceuticals, Inc. | $34.13 |
| Celgene Corporation | $31.94 |
| Daiichi Sankyo Inc. | $24.17 |
| Regeneron Healthcare Solutions, Inc. | $22.08 |
| Consulting Fee | $12,430 |
|---|---|
| Food and Beverage | $857 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099142;GTF;11653957 | $12,430 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $22,090 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Kite Pharma, Inc. - A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5)
Kite Pharma, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.